drugset

drugset / Trial / NCT01519778

A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

NCT01519778 ↗

Phase 2 Completed 200 enrolled Merck & Co., Inc. Bayer · collab

NaSingle-groupOpen-labelOther

Summary

Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.

Timeline

Start: 2012-02-15
Primary completion: 2012-08-27
Completion: 2012-08-27

Publications

Results Powers JH 3rd, Das AF, De Anda C, Prokocimer P. Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain. Contemp Clin Trials. 2016 Sep;50:265-72. doi: 10.1016/j.cct.2016.08.010. Epub 2016 Aug 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tedizolid	Small molecule	200 mg	Oral

Indications